These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28497239)

  • 1. Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry.
    Kawabata H; Tohyama K; Matsuda A; Araseki K; Hata T; Suzuki T; Kayano H; Shimbo K; Zaike Y; Usuki K; Chiba S; Ishikawa T; Arima N; Nogawa M; Ohta A; Miyazaki Y; Mitani K; Ozawa K; Arai S; Kurokawa M; Takaori-Kondo A;
    Int J Hematol; 2017 Sep; 106(3):375-384. PubMed ID: 28497239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy.
    Gauthier J; Damaj G; Langlois C; Robin M; Michallet M; Chevallier P; Beguin Y; N'guyen S; Bories P; Blaise D; Cornillon J; Clavert A; Mohty M; Huynh A; Thiébaut-Bertrand A; Vigouroux S; Duhamel A; Yakoub-Agha I
    Transplantation; 2015 Aug; 99(8):1672-80. PubMed ID: 25769079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
    Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
    Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
    van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
    Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
    Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
    J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
    van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
    Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
    Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
    Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
    Br J Haematol; 2018 Jun; 181(5):614-627. PubMed ID: 29707769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.
    Lee YJ; Park SW; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Lee WS; Lee SM; Joo YD; Kim H; Lee HS; Kim YS; Cho YY; Moon JH; Sohn SK
    Ann Hematol; 2016 Oct; 95(11):1795-804. PubMed ID: 27530461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?
    Zeidan AM; Sekeres MA; Wang XF; Al Ali N; Garcia-Manero G; Steensma DP; Roboz G; Barnard J; Padron E; DeZern A; Maciejewski JP; List AF; Komrokji RS;
    Am J Hematol; 2015 Nov; 90(11):1036-40. PubMed ID: 26284571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study.
    Germing U; Lauseker M; Hildebrandt B; Symeonidis A; Cermak J; Fenaux P; Kelaidi C; Pfeilstöcker M; Nösslinger T; Sekeres M; Maciejewski J; Haase D; Schanz J; Seymour J; Kenealy M; Weide R; Lübbert M; Platzbecker U; Valent P; Götze K; Stauder R; Blum S; Kreuzer KA; Schlenk R; Ganser A; Hofmann WK; Aul C; Krieger O; Kündgen A; Haas R; Hasford J; Giagounidis A
    Leukemia; 2012 Jun; 26(6):1286-92. PubMed ID: 22289990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.
    de Swart L; Smith A; Johnston TW; Haase D; Droste J; Fenaux P; Symeonidis A; Sanz G; Hellström-Lindberg E; Cermák J; Germing U; Stauder R; Georgescu O; MacKenzie M; Malcovati L; Holm MS; Almeida AM; Mądry K; Slama B; Guerci-Bresler A; Sanhes L; Beyne-Rauzy O; Luño E; Bowen D; de Witte T
    Br J Haematol; 2015 Aug; 170(3):372-83. PubMed ID: 25907546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes.
    Montoro J; Pomares H; Villacampa G; Merchán B; Molero A; Alonso E; Gallur L; Grau J; Salamero O; Roldán E; Saumell S; Ortega M; Sureda A; Bosch F; Arnan M; Valcárcel D
    Leuk Lymphoma; 2019 Jun; 60(6):1522-1527. PubMed ID: 30499738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
    Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Quarna J; Lazzarino M; Bernasconi C
    Leukemia; 2005 Aug; 19(8):1424-31. PubMed ID: 15920496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytogenetic profile in patients with primary myelodysplastic syndrome].
    Gritsaev SV; Martynkevich IS; Petrova EV; Martynenko LS; Ivanova MP; Aksenova VIu; Tsybakova NIu; Potikhonova NA; Abdulkadyrov KM
    Ter Arkh; 2013; 85(7):43-9. PubMed ID: 24137946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.
    Valcárcel D; Sanz G; Ortega M; Nomdedeu B; Luño E; Diez-Campelo M; Ardanaz MT; Pedro C; Montoro J; Collado R; Andreu R; Marco V; Cedena MT; de Paz R; Tormo M; Xicoy B; Ramos F; Bargay J; Gonzalez B; Brunet S; Muñoz JA; Gomez V; Bailén A; Sanchez J; Merchán B; del Cañizo C; Vallespí T;
    Lancet Haematol; 2015 Jun; 2(6):e260-6. PubMed ID: 26688236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
    Germing U; Hildebrandt B; Pfeilstöcker M; Nösslinger T; Valent P; Fonatsch C; Lübbert M; Haase D; Steidl C; Krieger O; Stauder R; Giagounidis AA; Strupp C; Kündgen A; Mueller T; Haas R; Gattermann N; Aul C
    Leukemia; 2005 Dec; 19(12):2223-31. PubMed ID: 16193087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
    Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS
    Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.